Addition of three new sarcoma probes produces largest portfolio on the market
Oxford, UK – 15 December 2016. Oxford Gene Technology (OGT), The Molecular Genetics Company, has expanded its range of Cytocell Aquarius® fluorescence in situ hybridisation (FISH) probes for pathology. OGT has introduced three new probes: FUS Breakapart and FOXO1 Breakapart, both carrying the CE-IVD label – and TFE3 Breakapart, for research use only. This expansion reinforces OGT’s commitment to providing the most comprehensive and up-to-date range available, facilitating cancer research and diagnosis.
Developed in response to customer need, the genes for both FUS and FOXO1 are both implicated in several debilitating neoplastic diseases. Recurrent rearrangements involving the FUS gene with a number of different partner genes have been reported in various types of neoplastic disease, notably soft tissue sarcomas and acute myeloid leukaemia. Translocations involving the FOXO1 gene are associated with around 80% of cases of alveolar rhabdomyosarcoma.
Commenting on the latest launch of Aquarius FISH probes, Steve Chatters, Senior Product Manager for Pathology at OGT, explained: “These new probes clearly show OGT’s commitment to being a market leader for high-quality FISH probes in the fast-moving field of cancer research; with over 20 new FISH probes released in the last year, Cytocell’s FISH portfolio is second-to-none in both range and quality. We are committed to keeping up with our customers’ expectations by further expanding the Cytocell cancer FISH probe range in 2017.”
Thanks to their excellent specificity, Cytocell Aquarius FISH probes deliver high-intensity signals with minimal background fluorescence. Probes are supplied as ready-to-use, premixed solutions to minimise the risks of experimental errors, delivering confidence in results.
Within the Cytocell portfolio, FUS Proximal Probe Red, FUS Distal Probe Green, FOXO1 Proximal Probe Green, FOXO1 Distal Probe Red, TFE3 Proximal Probe Red and TFE3 Distal Probe Green have been released as Analyte Specific Reagents (ASRs) in the United States.
To find out more, please visit www.cytocell.com.
For further information, please contact: Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684
E: contact@ogt.com ; W: www.ogt.com ; Twitter: @OxfordGeneTech
Notes for editors:
About Oxford Gene Technology
Oxford Gene Technology (OGT) provides world-class genetics research solutions to leading clinical and academic research institutions. Founded by Professor Sir Edwin Southern, and with customers in over 60 countries worldwide, OGT has a strong reputation and increasing share in the large and growing genomic medicine market. The Company’s Cytocell®, CytoSure™ and SureSeq™ range of fluorescence in situ hybridisation (FISH), microarray and next generation sequencing (NGS) products deliver high-quality genetic analysis, enabling accurate identification and confirmation of the causative variation underlying genetic disease.
For more information on the Company, please visit our website at www.ogt.com
